Sam Brusco, Associate Editor05.29.24
Sight Sciences has published a new analysis of study data from ROMEO (Retrospective, Observational, Multicenter Evaluation of OMNI).
The new analysis evaluated the link between glaucoma severity and intraocular pressure (IOP) and medication outcomes for patients treated with the OMNI surgical system. The results were published in the journal Clinical Ophthalmology.
OMNI allows a procedure to restore aqueous outflow of glaucomatous eyes by addressing three areas of outflow resistance related to the disease.
Findings suggested ab interno canaloplasty with trabeculotomy using OMNI effectively lowered IOP and reduced medication usage in advanced glaucoma patients as it was in mild and moderate glaucoma patients. Sight Sciences said the data disputes the belief that advanced disease stage is a barrier to successful minimally invasive glaucoma surgery (MIGS) outcomes.
70% of eyes had reduced IOP at month 12 with 92% of those achieving 11 mmHg or less. Medication reduction was seen among all severity groups, with the majority of patients showing reduction of at least one medication (50-69%).
"Clinical trials and real-world results continue to demonstrate favorable OMNI treatment outcomes across different stages of glaucoma," said Sight Sciences co-founder and CEO Paul Badawi. "These findings reinforce our dedication to offering effective treatment options for glaucoma patients at every stage of the disease and also fuel our initiatives to continue reimagining eyecare with transformative technology and an interventional mindset."
The new analysis evaluated the link between glaucoma severity and intraocular pressure (IOP) and medication outcomes for patients treated with the OMNI surgical system. The results were published in the journal Clinical Ophthalmology.
OMNI allows a procedure to restore aqueous outflow of glaucomatous eyes by addressing three areas of outflow resistance related to the disease.
Findings suggested ab interno canaloplasty with trabeculotomy using OMNI effectively lowered IOP and reduced medication usage in advanced glaucoma patients as it was in mild and moderate glaucoma patients. Sight Sciences said the data disputes the belief that advanced disease stage is a barrier to successful minimally invasive glaucoma surgery (MIGS) outcomes.
70% of eyes had reduced IOP at month 12 with 92% of those achieving 11 mmHg or less. Medication reduction was seen among all severity groups, with the majority of patients showing reduction of at least one medication (50-69%).
"Clinical trials and real-world results continue to demonstrate favorable OMNI treatment outcomes across different stages of glaucoma," said Sight Sciences co-founder and CEO Paul Badawi. "These findings reinforce our dedication to offering effective treatment options for glaucoma patients at every stage of the disease and also fuel our initiatives to continue reimagining eyecare with transformative technology and an interventional mindset."